Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

Maria L. Ascierto, Andrea Worschech, Zhiya Yu, Sharon Adams, Jennifer Reinboth, Nanhai G. Chen, Zoltan Pos, Rahul Roychoudhuri, Giovanni Di Pasquale, Davide Bedognetti, Lorenzo Uccellini, Fabio Rossano, Paolo A. Ascierto, David F. Stroncek, Nicholas P. Restifo, Ena Wang, Aladar A. Szalay, Francesco M. Marincola

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo.Methods: In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection.Results: We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection.Conclusions: Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.

Original languageEnglish
Article number451
JournalBMC Cancer
Volume11
DOIs
Publication statusPublished - 19 Oct 2011
Externally publishedYes

Fingerprint

Oncolytic Viruses
Vaccinia virus
Cell Line
Virus Diseases
Neoplasms
Vesicular Stomatitis
Infection
Viruses
Tropism
Complementary Therapies
B-Lymphocytes
Therapeutics
Phenotype

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Ascierto, M. L., Worschech, A., Yu, Z., Adams, S., Reinboth, J., Chen, N. G., ... Marincola, F. M. (2011). Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer, 11, [451]. https://doi.org/10.1186/1471-2407-11-451

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. / Ascierto, Maria L.; Worschech, Andrea; Yu, Zhiya; Adams, Sharon; Reinboth, Jennifer; Chen, Nanhai G.; Pos, Zoltan; Roychoudhuri, Rahul; Di Pasquale, Giovanni; Bedognetti, Davide; Uccellini, Lorenzo; Rossano, Fabio; Ascierto, Paolo A.; Stroncek, David F.; Restifo, Nicholas P.; Wang, Ena; Szalay, Aladar A.; Marincola, Francesco M.

In: BMC Cancer, Vol. 11, 451, 19.10.2011.

Research output: Contribution to journalArticle

Ascierto, ML, Worschech, A, Yu, Z, Adams, S, Reinboth, J, Chen, NG, Pos, Z, Roychoudhuri, R, Di Pasquale, G, Bedognetti, D, Uccellini, L, Rossano, F, Ascierto, PA, Stroncek, DF, Restifo, NP, Wang, E, Szalay, AA & Marincola, FM 2011, 'Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68', BMC Cancer, vol. 11, 451. https://doi.org/10.1186/1471-2407-11-451
Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG et al. Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer. 2011 Oct 19;11. 451. https://doi.org/10.1186/1471-2407-11-451
Ascierto, Maria L. ; Worschech, Andrea ; Yu, Zhiya ; Adams, Sharon ; Reinboth, Jennifer ; Chen, Nanhai G. ; Pos, Zoltan ; Roychoudhuri, Rahul ; Di Pasquale, Giovanni ; Bedognetti, Davide ; Uccellini, Lorenzo ; Rossano, Fabio ; Ascierto, Paolo A. ; Stroncek, David F. ; Restifo, Nicholas P. ; Wang, Ena ; Szalay, Aladar A. ; Marincola, Francesco M. / Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. In: BMC Cancer. 2011 ; Vol. 11.
@article{f861b22f1c5241d68686fedccde84614,
title = "Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68",
abstract = "Background: Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo.Methods: In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection.Results: We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection.Conclusions: Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.",
author = "Ascierto, {Maria L.} and Andrea Worschech and Zhiya Yu and Sharon Adams and Jennifer Reinboth and Chen, {Nanhai G.} and Zoltan Pos and Rahul Roychoudhuri and {Di Pasquale}, Giovanni and Davide Bedognetti and Lorenzo Uccellini and Fabio Rossano and Ascierto, {Paolo A.} and Stroncek, {David F.} and Restifo, {Nicholas P.} and Ena Wang and Szalay, {Aladar A.} and Marincola, {Francesco M.}",
year = "2011",
month = "10",
day = "19",
doi = "10.1186/1471-2407-11-451",
language = "English",
volume = "11",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

AU - Ascierto, Maria L.

AU - Worschech, Andrea

AU - Yu, Zhiya

AU - Adams, Sharon

AU - Reinboth, Jennifer

AU - Chen, Nanhai G.

AU - Pos, Zoltan

AU - Roychoudhuri, Rahul

AU - Di Pasquale, Giovanni

AU - Bedognetti, Davide

AU - Uccellini, Lorenzo

AU - Rossano, Fabio

AU - Ascierto, Paolo A.

AU - Stroncek, David F.

AU - Restifo, Nicholas P.

AU - Wang, Ena

AU - Szalay, Aladar A.

AU - Marincola, Francesco M.

PY - 2011/10/19

Y1 - 2011/10/19

N2 - Background: Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo.Methods: In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection.Results: We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection.Conclusions: Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.

AB - Background: Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo.Methods: In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection.Results: We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection.Conclusions: Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.

UR - http://www.scopus.com/inward/record.url?scp=80054110110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054110110&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-11-451

DO - 10.1186/1471-2407-11-451

M3 - Article

VL - 11

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 451

ER -